Tags

Type your tag names separated by a space and hit enter

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Breast J. 2005 Nov-Dec; 11(6):433-9.BJ

Abstract

The HER-2/neu gene is a proto-oncogene that is amplified in 10-30% of breast cancers. New drugs for targeted therapy, such as Herceptin, are effective for patients with HER-2/neu-positive tumors, making it necessary to have a noncostly and accurate method to assess HER-2/neu status. We studied the correlation of findings made by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) staining and the possibility of combining IHC and other clinicopathologic characteristics of breast tumors to predict FISH-determined HER-2/neu status. The clinicopathologic characteristics analyzed were the size of the tumor, p53, lymph-vascular invasion, estrogen/progesterone receptors (ER/PR), tumor grade, axillary lymph node status, and patient age. A total of 199 cases of invasive breast cancer studied at the UCLA Pathology Laboratory during 2003 were included in this study. Tumors with IHC 0, 1+, 2+, and 3+ scores were found to be FISH positive in 3.5%, 6.4%, 25.7%, and 81.5% of the respective groups. Our study showed a strong association between the FISH-negative and IHC scored 0 and 1+ tumors, suggesting that the FISH test may not be necessary in these cases (p<0.0001). Although the concordance between IHC 3+ and FISH positive is high, 18% of the patients with overexpression of HER-2/neu fail to show gene amplification by FISH. HER-2/neu positivity was found to be proportionally associated with increasing grade in infiltrating ductal carcinoma (p<0.0001). p53-positive tumors are more likely to be HER-2/neu amplified (p=0.0003). Tumors that are negative for ER/PR are also associated with HER-2/neu positivity by FISH (31.15%, p=0.0016). FISH-determined HER-2/neu status is not associated with histologic type, tumor size, nodal status, lymph-vascular invasion, or patient age.

Authors+Show Affiliations

Department of Surgery, Revlon/UCLA Breast Center, UCLA Medical Center, Gonda/UCLA Breast Cancer Research Laboratory, Los Angeles, California 90095-7028, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16297088

Citation

Prati, Raquel, et al. "Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer." The Breast Journal, vol. 11, no. 6, 2005, pp. 433-9.
Prati R, Apple SK, He J, et al. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005;11(6):433-9.
Prati, R., Apple, S. K., He, J., Gornbein, J. A., & Chang, H. R. (2005). Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. The Breast Journal, 11(6), 433-9.
Prati R, et al. Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer. Breast J. 2005 Nov-Dec;11(6):433-9. PubMed PMID: 16297088.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. AU - Prati,Raquel, AU - Apple,Sophia K, AU - He,Jianbo, AU - Gornbein,Jeffrey A, AU - Chang,Helena R, PY - 2005/11/22/pubmed PY - 2005/12/15/medline PY - 2005/11/22/entrez SP - 433 EP - 9 JF - The breast journal JO - Breast J VL - 11 IS - 6 N2 - The HER-2/neu gene is a proto-oncogene that is amplified in 10-30% of breast cancers. New drugs for targeted therapy, such as Herceptin, are effective for patients with HER-2/neu-positive tumors, making it necessary to have a noncostly and accurate method to assess HER-2/neu status. We studied the correlation of findings made by fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) staining and the possibility of combining IHC and other clinicopathologic characteristics of breast tumors to predict FISH-determined HER-2/neu status. The clinicopathologic characteristics analyzed were the size of the tumor, p53, lymph-vascular invasion, estrogen/progesterone receptors (ER/PR), tumor grade, axillary lymph node status, and patient age. A total of 199 cases of invasive breast cancer studied at the UCLA Pathology Laboratory during 2003 were included in this study. Tumors with IHC 0, 1+, 2+, and 3+ scores were found to be FISH positive in 3.5%, 6.4%, 25.7%, and 81.5% of the respective groups. Our study showed a strong association between the FISH-negative and IHC scored 0 and 1+ tumors, suggesting that the FISH test may not be necessary in these cases (p<0.0001). Although the concordance between IHC 3+ and FISH positive is high, 18% of the patients with overexpression of HER-2/neu fail to show gene amplification by FISH. HER-2/neu positivity was found to be proportionally associated with increasing grade in infiltrating ductal carcinoma (p<0.0001). p53-positive tumors are more likely to be HER-2/neu amplified (p=0.0003). Tumors that are negative for ER/PR are also associated with HER-2/neu positivity by FISH (31.15%, p=0.0016). FISH-determined HER-2/neu status is not associated with histologic type, tumor size, nodal status, lymph-vascular invasion, or patient age. SN - 1075-122X UR - https://www.unboundmedicine.com/medline/citation/16297088/Histopathologic_characteristics_predicting_HER_2/neu_amplification_in_breast_cancer_ L2 - https://doi.org/10.1111/j.1075-122X.2005.00125.x DB - PRIME DP - Unbound Medicine ER -